SEC Form 4 · accession 0001104659-17-025903
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Aryeh
Director
Period of report
Sep 16, 2016
Accepted (ET)
Apr 25, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF1 | Sep 16, 2016 | P | 295,929 | $5.855 | A | 343,216 | I | By JALAA Equities, LP |
| Common Shares, without par value | holding | — | — | — | 7,500 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Securities are owned by JALAA Equities, LP, of which the Reporting Person is the general partner. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed to be the beneficial owner of the securities owned by JALAA Equities, LP.